A phase III trial of TPI-287 in glioblastoma multiforme

Trial Profile

A phase III trial of TPI-287 in glioblastoma multiforme

Planning
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs TPI 287 (Primary)
  • Indications Glioblastoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Cortice Biosciences
  • Most Recent Events

    • 18 Nov 2016 According to a Cortice Biosciences media release, data from another Phase I/II study (see profile 236577) will be utilized to design this trial with guidance provided by FDA.
    • 08 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top